Effects of Macrolides on Asthma Control

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00852579
Recruitment Status : Completed
First Posted : February 27, 2009
Last Update Posted : October 19, 2011
University of Glasgow
NHS Greater Glasgow and Clyde
Information provided by (Responsible Party):
Euan J Cameron, University of Glasgow

February 26, 2009
February 27, 2009
October 19, 2011
March 2009
August 2011   (Final data collection date for primary outcome measure)
Peak expiratory flow rate. [ Time Frame: 12 weeks ]
Same as current
Complete list of historical versions of study NCT00852579 on Archive Site
  • Spirometry [ Time Frame: 12 weeks ]
  • Asthma control score [ Time Frame: 12 weeks ]
  • Average of last 7 days PEF measurements [ Time Frame: 12 weeks ]
  • Sputum cell counts [ Time Frame: 12 weeks ]
  • Fraction of expired nitric oxide [ Time Frame: 12 weeks ]
  • Airway responsiveness to methacholine [ Time Frame: 12 weeks ]
  • Exacerbation rates [ Time Frame: 12 weeks ]
  • Cough score [ Time Frame: 12 weeks ]
  • Diary symptom score [ Time Frame: 12 weeks ]
Same as current
Not Provided
Not Provided
Effects of Macrolides on Asthma Control
Effects of Macrolides on Asthma Control, Airway Inflammation and Bacterial Colonisation in Smokers With Asthma.
Asthma is a common disease in Westernised societies, affecting up to 10% of the population. Corticosteroids are the most effective treatment for asthma but the therapeutic response varies considerably between individuals. A major cause of corticosteroid insensitivity in asthma is cigarette smoking. Active cigarette smoking occurs in over 25% of adults with asthma and a further 25% are ex-smokers. In a series of proof of concept clinical studies the investigators demonstrated for the first time that the efficacy of inhaled and oral corticosteroids is markedly impaired in smokers with asthma and to a lesser extent in ex-smokers with asthma. Active cigarette smoking has other detrimental effects on asthma morbidity including more severe symptoms, increased rates of hospitalisation, and accelerated decline in lung function. Smoking cessation advice is often ineffective because many adult smokers with asthma do not believe that they are personally at risk from their smoking, take many years until stopping smoking and frequently restart smoking after quitting. Alternative or additional drugs to corticosteroids are needed for smokers with asthma who are unable to obtain the clinical benefits associated with stopping smoking. In a proof of concept clinical trial the investigators will test the hypothesis that macrolides improve asthma control and reduce sputum neutrophil counts of smokers with chronic asthma.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: Azithromycin
    Daily dose 250mg
  • Drug: Placebo
  • Experimental: 1
    Active treatment.
    Intervention: Drug: Azithromycin
  • Placebo Comparator: 2
    Placebo control group.
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of asthma
  • Age 18-70
  • Current smoker
  • Duration of symptoms >1yr with stability for 4 weeks
  • Able to maintain asthma without exacerbations during run in period
  • Able to wean off other asthma medication

Exclusion Criteria:

  • Ex-smokers or never smokers
  • Planning to quit smoking during duration of trial
  • Patients with unstable asthma
  • Patients with current epilepsy, psychosis or history of significant atrial or ventricular tachyarrhythmia
  • Corrected QT-interval greater than 450msec in women, 430msec in men
  • Low potassium levels. If can be corrected then screening can continue with confirmation of normal levels prior to taking study medication
  • Liver disease (ALT and/or AST levels 2 or more times ULN)
  • Significant renal disease (Creatinine or urea levels 2 or more times ULN)
  • Any previous severe adverse reactions to macrolides
  • Patients who are known to have specific IgE sensitivity or skin test positivity to grass pollen and a history of worsening of asthma due to hay fever will not be recruited from mid May to the end of July
  • Upper or lower respiratory tract infection in the 4 weeks prior to randomisation. Run in period can be prolonged in this situation to have 4 weeks with no respiratory infection prior to randomisation.
  • Patients who require medications known to interact with azithromycin
  • On other immunosuppressants or chronic antibiotics
  • Weight less than 45kg
  • Frequent asthma exacerbations (greater than 4) requiring oral corticosteroids in the year prior to randomisation
  • Current or past diagnosis of allergic-bronchopulmonary-aspergillosis
  • Pregnancy and breast feeding
  • Mental impairment or language difficulties that makes informed consent not possible
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
EUDRACT 2008-007240-34
MRC Grant G0701626
NRES 09/S0703/23
Not Provided
Not Provided
Euan J Cameron, University of Glasgow
Euan J Cameron
  • University of Glasgow
  • NHS Greater Glasgow and Clyde
Principal Investigator: Neil C Thomson, FRCP University of Glasgow
University of Glasgow
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP